- #1223 ALLN-346 a urate degrading enzyme in a pig model of gout
- #L06 Emapalumab for treating MAS in systemic JIA patients
- #1890 and 2357 Methotrexate Safety from CIRT
- #1240 Anakinra in acute gout – anaGO study
- #2292, #2279 When to withdraw biologics in RA patients who become pregnant
- #633, #631 Delays in referral of LBP
- #196 VTE risk and future ASCVD risk
- #2566 Polypharmacy
- #860 EMBRACE – Belimumab in Blacks
Dr. Robinson highlights a presentation on non-radiographic axial spondyloarthritis presented at the 2019 ACR/ARP annual meeting in Atlanta.
Drs. Rachel Tate, Kathryn Dao, Kanika Monga, Courtney Crayne, and Arundathi Jayatillekey discuss issues, ideas and opportunities around the topic of women in rheumatology, with special guest Dr. Eric Ruderman, at the 2019 ACR/ARP Annual Meeting in Atlanta.
Drs. Eric Ruderman, Alexis Ogdie, Jessica Walsh, and Jose Scher discuss the giselkumab trials, where IL-23 inhibitors fit in practice, ixekizumab withdrawal, and more that presented at the 2019 ACR/ARP annual meeting in Atlanta.
Dr. David Liew discusses abstract #2091 The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients presented at the 2019 ACR/ARP annual meeting in Atlanta.
Dr. Valenzuela describes a variety of pearls for evaluating PSA patients at the 2019 ACR/ARP annual meeting in Atlanta.
Dr. Dao shares several vasculitis pearls presented at the 2019 ACR/ARP annual meeting in Atlanta.
Drs. Jack Cush, Christopher Ritchlin, Sophia Ramiro, Lianne Gensler, and Jessica Walsh discuss interesting new trials and data presented in ankylosing spondylitis and spondyloarthritis at the 2019 ACR/ARP annual meeting in Atlanta.
Drs. Jack Cush, Nicola Dalbreth, Ken Saag and Robert Keenan discuss several gout presentations, including tart cherry, safety and efficacy of therapies, quality of life issues and more at the 2019 ACR/ARP annual meeting in Atlanta.
Dr Irwin Lim _connectedcare
Hand OA responds to 10mg/d Pred over 6wks. As expected symptoms return on cessation Anecdotally, there are people who do well on pragmatic, long term low dose eg 5mg or less/d #ACR19 @rheumnow Abst1760 https://t.co/FtE9vHb655
Dr. John Cush RheumNow
#ACR19 Rheumatology RoundUp - Kavanaughs Picks: 2505 PsA prevention 1366 Self Joint exams 1120 Rheum burnout 1310 OA Hx 565 Enteropathic arthritis Recs 1823 MRE dx of SI 2773 Machine learning 2772 Antiinflammatory diet in RA 1359 Synovial Bx
1223 ALLN-346 Urate Degrading Enzyme
L06 Emapalumab in MAS
1890 2357 MTX Safety
Dr. John Cush RheumNow
It is thought that NLRP3 mutations lead to the unc…
Holy Molly! TNFi (etanercept, adalimumab, infliximab, or golimumab) completely prevented stokes in patients with DADA2. #ACR19 @RheumNow
"But methotrexate is in serum…
RP is typica…